Bevacizumab is a targeted therapy used in the treatment of colorectal, lung, kidney, and certain brain cancers. It is often used in combination with chemotherapy.

It is a monoclonal antibody that targets angiogenesis, the process by which tumors develop new blood vessels.

Bevacizumab works by binding to vascular endothelial growth factor (VEGF), a protein that promotes blood vessel formation. By inhibiting VEGF, it may reduce the tumor’s ability to develop its blood supply, which may slow tumor growth.

Because blood vessel formation is also important in normal tissues, side effects such as high blood pressure or delayed wound healing may occur.